ATE90384T1 - Rekombinante virusproteine begleitet von lymphadenopathischem syndrom und/oder ''acquired immune deficiency syndrome'' (aids). - Google Patents

Rekombinante virusproteine begleitet von lymphadenopathischem syndrom und/oder ''acquired immune deficiency syndrome'' (aids).

Info

Publication number
ATE90384T1
ATE90384T1 AT85307860T AT85307860T ATE90384T1 AT E90384 T1 ATE90384 T1 AT E90384T1 AT 85307860 T AT85307860 T AT 85307860T AT 85307860 T AT85307860 T AT 85307860T AT E90384 T1 ATE90384 T1 AT E90384T1
Authority
AT
Austria
Prior art keywords
syndrome
lymphadenopathic
aids
recombinant virus
immune deficiency
Prior art date
Application number
AT85307860T
Other languages
English (en)
Inventor
Paul A Luciw
Dino Dina
Kathelyn Steimer
Ray Sanchez Pescador
Carlos George-Nascimento
Deborah Parkes
Rob Hallewell
Philip J Barr
Martha Truett
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27418170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE90384(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE90384T1 publication Critical patent/ATE90384T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C12N2830/704—S. cerevisiae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/82—Subcellular parts of microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT85307860T 1984-10-31 1985-10-30 Rekombinante virusproteine begleitet von lymphadenopathischem syndrom und/oder ''acquired immune deficiency syndrome'' (aids). ATE90384T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66750184A 1984-10-31 1984-10-31
US69653485A 1985-01-30 1985-01-30
US77344785A 1985-09-06 1985-09-06
EP85307860A EP0181150B2 (de) 1984-10-31 1985-10-30 Rekombinante Virusproteine begleitet von lymphadenopathischem Syndrom und/oder "Acquired Immune Deficiency Syndrome" (AIDS)

Publications (1)

Publication Number Publication Date
ATE90384T1 true ATE90384T1 (de) 1993-06-15

Family

ID=27418170

Family Applications (3)

Application Number Title Priority Date Filing Date
AT92201711T ATE295881T1 (de) 1984-10-31 1985-10-30 Rekombinante proteine von mit lymphadenopathiesyndrom und/oder erworbenem immunschwächesyndrom assoziierten viren
AT85307860T ATE90384T1 (de) 1984-10-31 1985-10-30 Rekombinante virusproteine begleitet von lymphadenopathischem syndrom und/oder ''acquired immune deficiency syndrome'' (aids).
AT02077411T ATE297468T1 (de) 1984-10-31 1985-10-30 Rekombinante proteine von mit lymphadenopathiesyndrom und/oder erworbenem immunschwächesyndrom assoziierten viren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92201711T ATE295881T1 (de) 1984-10-31 1985-10-30 Rekombinante proteine von mit lymphadenopathiesyndrom und/oder erworbenem immunschwächesyndrom assoziierten viren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02077411T ATE297468T1 (de) 1984-10-31 1985-10-30 Rekombinante proteine von mit lymphadenopathiesyndrom und/oder erworbenem immunschwächesyndrom assoziierten viren

Country Status (9)

Country Link
US (5) US5156949A (de)
EP (3) EP0518443B1 (de)
JP (7) JP2865283B2 (de)
AT (3) ATE295881T1 (de)
CA (2) CA1341423C (de)
DE (7) DE3588253T2 (de)
HK (1) HK102495A (de)
LU (1) LU91049I2 (de)
NL (2) NL300137I2 (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123228B1 (de) * 1983-04-25 1993-09-29 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US5217861A (en) * 1983-09-15 1993-06-08 Institut Pasteur Antigen of a human retrovirus, namely p18 protein of human immunodeficiency virus (HIV), compositions containing the antigen, a diagnostic method for detecting acquired immune deficiency syndrome (AIDS) and pre-AIDS and a kit therefor
US7217508B1 (en) 1983-09-15 2007-05-15 Institut Pasteur Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1)
US7232654B1 (en) 1983-09-15 2007-06-19 Institut Pasteur DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)
US6395495B1 (en) 1983-09-15 2002-05-28 Institut Pasteur Methods and kits for detecting antibodies against an HIV variant
US6600023B1 (en) 1983-09-15 2003-07-29 Institut Pasteur Antibody directed against HIV-1 P25 antigen
US7205102B1 (en) 1983-09-15 2007-04-17 Institut Pasteur Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA
GB8423659D0 (en) 1984-09-19 1984-10-24 Pasteur Institut Cloned dna sequences
US6428952B1 (en) * 1983-09-15 2002-08-06 Institut Pasteur Methods and kits employing LAV antigens for the detection of HIV-1-specific antibodies
GB8429099D0 (en) * 1984-11-16 1984-12-27 Pasteur Institut Closed dna sequences
US7351412B1 (en) 1983-12-05 2008-04-01 Institut Pasteur Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA
ATE102250T1 (de) * 1984-05-11 1994-03-15 Chiron Corp Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.
US7815916B1 (en) * 1984-08-22 2010-10-19 The United States Of America As Represented By The Secretary Of Health And Human Services Cloning and expression of HTLV-III DNA
US9309574B1 (en) 1984-08-22 2016-04-12 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Molecular cloning of HIV-1 from immortalized cell lines
US9328391B1 (en) 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
US5705612A (en) 1984-10-18 1998-01-06 Institut Pasteur And Centre National De La Recherche Scientifique NEF peptide encoded by human immunodefiency virus type 1 (HIV-1)
DE3588254T2 (de) * 1984-10-18 2008-06-26 Institut Pasteur GAG-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
US7045130B1 (en) 1984-10-18 2006-05-16 Institut Pasteur Antibodies against antigens of human immunodeficiency virus (HIV-1)
US7273695B1 (en) * 1984-10-31 2007-09-25 Novartis Vaccines And Diagnostics, Inc. HIV immunoassays using synthetic envelope polypeptides
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US7285271B1 (en) 1984-10-31 2007-10-23 Novartis Vaccines And Diagnostics, Inc. Antigenic composition comprising an HIV gag or env polypeptide
US7393949B1 (en) 1987-12-24 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Human immunodeficiency virus (HIV) nucleotide sequences
US6894152B1 (en) 1984-11-16 2005-05-17 Institut Pasteur Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
JP2869063B2 (ja) * 1985-04-08 1999-03-10 ジエネテイツク システムズ コ−ポレイシヨン ＬＡＶに対する抗体と免疫的に反応性であるｇａｇによりコードされたペプチドの発現及び使用
IE64785B1 (en) * 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
DE3650011T2 (de) * 1985-04-08 1994-11-17 Genetic Systems Corp EXPRESSION UND DIAGNOSE MIT gag-KODIERTEN PEPTIDEN, DIE MIT ANTIKÖRPERN GEGEN LAV IMMUNOLOGISCH REAKTIV SIND.
DK171119B1 (da) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
US5773210A (en) * 1985-04-19 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
JP2564268B2 (ja) * 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
FR2593519B1 (fr) * 1985-09-25 1994-01-07 Oncogen Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin
DE3688051T2 (de) * 1985-12-17 1993-06-24 Akzo Nv Immunochemisches reagenz.
DE3674555D1 (de) * 1985-12-20 1990-10-31 Abbott Lab Immuntest fuer antikoerper gegen htlv-iii.
JPS62164696A (ja) * 1986-01-06 1987-07-21 エフ．ホフマン　―　ラ　ロシュ　アーゲー ＨＴＬＶ−３ｇａｇ遺伝子の発現
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4808536A (en) * 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
US5075211A (en) * 1986-03-26 1991-12-24 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US4943627A (en) * 1986-06-12 1990-07-24 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US5017688A (en) * 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US5034511A (en) 1987-04-13 1991-07-23 Institut Pasteur Variant of LAV viruses
EP0525828A3 (en) * 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
DE3636540A1 (de) * 1986-10-27 1988-04-28 Behringwerke Ag Verfahren zur bestimmung von anti-hiv, mittel dazu und ihre verwendung in diesem verfahren
SE8701628D0 (sv) * 1987-04-16 1987-04-16 Erling Norrby Medel for analys mm
EP0293792A3 (de) * 1987-06-01 1990-01-17 The Du Pont Merck Pharmaceutical Company Von menschlichem Immunmangelvirus GAG-kodierte Proteine
US5549924A (en) * 1987-07-17 1996-08-27 Robin Renee Thill Shlenker Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
US5679399A (en) 1987-07-17 1997-10-21 Bio Barrier, Inc. Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
US5447837A (en) * 1987-08-05 1995-09-05 Calypte, Inc. Multi-immunoassay diagnostic system for antigens or antibodies or both
US5118602A (en) * 1987-08-26 1992-06-02 The Regents Of The University Of California Feline T-lymphotropic lentivirus assay
DE3877294T2 (de) * 1987-09-04 1993-05-06 Int Murex Tech Corp Festphasenimmunoassay fuer einen antikoerper und hierbei verwendete biologische produkte.
JPS6474990A (en) * 1987-09-17 1989-03-20 Susumu Maeda Vector, recombinant dna, virus and production of protein
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5322769A (en) * 1988-03-11 1994-06-21 Abbott Laboratories Methods for using CKS fusion proteins
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
DE68918867T2 (de) * 1988-09-13 1995-02-16 Chiron Corp Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
US5656458A (en) * 1988-11-04 1997-08-12 Chiron Corporation Expression and processing of amino terminus acetylated FGF's in yeast
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
DE69013950T2 (de) * 1989-02-03 1995-03-30 Abbott Lab Monoklonaler Antikörper zur Unterscheidung HIV-2-seropositiver von HIV-1-seropositiven Individuen.
US5856088A (en) * 1989-07-11 1999-01-05 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
US6589734B1 (en) 1989-07-11 2003-07-08 Gen-Probe Incorporated Detection of HIV
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
JP2733138B2 (ja) † 1990-04-04 1998-03-30 カイロン コーポレイション 抗ｈｃｖ抗体の免疫アッセイに使用するｃ型肝炎ウイルス（ｈｃｖ）抗原の組合せ
WO1992006220A1 (en) * 1990-10-05 1992-04-16 President And Fellows Of Harvard College Detection and isolation of ligands
US5773211A (en) * 1991-07-10 1998-06-30 Abbott Laboratories Differentiation of HTLV-I and HTLV-II using synthetic peptides
US6352826B1 (en) * 1991-11-25 2002-03-05 Yoreh Biotechnologies, Ltd. Method and kit for the detection of retroviral specific antibodies in seronegative individuals
AU3934393A (en) * 1992-03-27 1993-11-08 Abbott Laboratories Assay verification control for analytical methods
JP3277045B2 (ja) * 1992-10-06 2002-04-22 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Ｈｉｖ−グループのレトロウイルスおよびその使用
KR100325554B1 (ko) 1993-03-26 2002-11-02 젠-프로브 인코포레이티드 사람의면역결핍 바이러스타입1의검출
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US20070202127A1 (en) * 1993-06-07 2007-08-30 Duke University Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
US6074646A (en) * 1993-10-26 2000-06-13 Board Of Regents, The University Of Texas System Nondenatured HIV envelope antigens for detecting early HIV-specific antibodies
US5695928A (en) 1993-12-10 1997-12-09 Novartis Corporation Rapid immunoassay for detection of antibodies or antigens incorporating simultaneous sample extraction and immunogenic reaction
US6025141A (en) * 1993-12-10 2000-02-15 The Canadian Red Cross Society Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US6319665B1 (en) 1994-06-07 2001-11-20 Inverness Medical Technology, Inc. Home test kit and method with telephone verification of results
CA2268372C (en) 1996-10-10 2012-11-27 Probe International Compositions and methods for treating viral infections
US6392029B1 (en) * 1997-05-09 2002-05-21 The Research Foundation Of State University Of New York HIV chemokines
US8765461B2 (en) 1997-05-09 2014-07-01 Linda B. Ludwig HIV antisense proteins
US20030118985A1 (en) * 1997-05-14 2003-06-26 Hunt Jeffrey C. Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
US5962665A (en) * 1997-06-16 1999-10-05 Abbott Laboratories Nucleic acid primers and probes for detecting HIV-1 and HIV-2
US6846905B2 (en) * 1997-08-15 2005-01-25 Abbott Laboratories Antigen constructs useful in the detection and differentiation of antibodies to HIV
KR20000006334A (ko) 1998-06-26 2000-01-25 이선경 바이러스코딩염기서열이전혀없는고효율레트로바이러스벡터
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
DK1141315T3 (da) 1998-12-31 2008-05-19 Novartis Vaccines & Diagnostic Modificerede HIV Env-polypeptider
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
US6235479B1 (en) 1999-04-13 2001-05-22 Bio Merieux, Inc. Methods and devices for performing analysis of a nucleic acid sample
DK1175497T3 (da) 1999-04-14 2010-05-31 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer
JP2004503205A (ja) 2000-02-04 2004-02-05 デューク・ユニバーシティー ヒト免疫不全ウイルスワクチン
AU2001268716A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel chimeric promoters
DE60040874D1 (de) 2000-09-01 2009-01-02 Gen Probe Inc Amplifizierung von hiv-1 sequenzen zur detektion ven einhergehen
EP1373524B1 (de) * 2000-10-13 2006-04-12 Chiron Corporation Fragmente der intron a von citomegalovirus
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
WO2002079470A1 (en) * 2001-03-30 2002-10-10 King A Christie Disease-specific promoter chimeras for gene expression
EP1427806A4 (de) * 2001-08-31 2006-04-26 Chiron Corp Antigene hiv-typ-b-polypeptide codierende polynukleotide, polypeptide und verwendungen davon
US20030091990A1 (en) * 2001-09-17 2003-05-15 Cloyd Miles W. Methods and compositions involving thymidine phosphorylase as a marker for HIV infection, aids progression, and drug resistance
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
AU2003212466A1 (en) * 2002-02-28 2003-09-16 Board Of Regents, The University Of Texas System Method and composition for detecting early hiv antibody
EP1709200B1 (de) 2003-12-03 2012-05-09 Abbott Laboratories Doppelsträngige lineare nukleinsäuresonde und deren verwendung
CA2579676A1 (en) 2004-09-08 2007-02-15 Hana Golding Compositions and methods for the detection of hiv-1/hiv-2 infection
DK2975139T3 (da) * 2004-09-30 2019-12-09 Gen Probe Inc Assay til at detektere og kvantificere hiv-1
US20080282331A1 (en) * 2004-10-08 2008-11-13 Advanced Network Technology Laboratories Pte Ltd User Provisioning With Multi-Factor Authentication
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
US20080299624A1 (en) * 2007-06-01 2008-12-04 Edward Heslop Continuous fermentation apparatus and method
ES2316302B1 (es) * 2007-09-27 2010-01-26 Fundacion Reina Mercedes Para La Investigacion Sanitaria Metodo de analisis inmunologico, su utilizacion y kit para su realizacion.
EP2385065A1 (de) 2007-11-01 2011-11-09 Perseid Therapeutics LLC Immunsuppressive Polypeptide und Nukleinsäuren
EP2433132B1 (de) 2009-05-21 2018-02-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Zusammensetzungen und verfahren zur detektion einer hiv-1/hiv-2-infektion
EP2451475A2 (de) 2009-07-06 2012-05-16 Novartis AG Selbstreplizierende rna-moleküle und ihre verwendung
US10113206B2 (en) 2010-02-24 2018-10-30 Grifols Therapeutics Inc. Methods, compositions, and kits for determining human immunodeficiency virus (HIV)
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2649896T3 (es) 2010-07-06 2018-01-16 Glaxosmithkline Biologicals Sa Emulsiones catiónicas de aceite en agua
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
CA2840965C (en) 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions
EP2729125B1 (de) 2011-07-06 2017-12-13 GlaxoSmithKline Biologicals SA Öl-in-wasser-emulsionen mit nukleinsäuren
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
MX2014004214A (es) 2011-10-11 2014-05-07 Novartis Ag Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
JP2016512241A (ja) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
MX2015012825A (es) 2013-03-14 2016-06-10 Abbott Lab Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc.
JP6505076B2 (ja) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
CN108778321A (zh) 2016-01-19 2018-11-09 辉瑞公司 癌症疫苗
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
IT201600116554A1 (it) * 2016-11-17 2018-05-17 Fond Ri Med Probiotic yeasts as novel vaccination vectors
RU2020100072A (ru) 2017-07-11 2021-08-11 Пфайзер Инк. Иммуногенные композиции, содержащие cea, muc1 и tert

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA443605A (en) 1947-08-12 Forrest David Surface grinder
IE52036B1 (en) 1979-05-24 1987-05-27 Univ California Non-passageable viruses
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
EP0062574A3 (de) 1981-03-31 1982-12-29 The Regents Of The University Of California Synthese von Virusproteinen
FR2506904A1 (fr) 1981-05-29 1982-12-03 Applic Catalytiques Ste Ly Procede de regulation d'une installation de chauffage et dispositif pour sa mise en oeuvre
DK368882A (da) 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4468382A (en) 1982-07-15 1984-08-28 New England Medical Center, Inc. Polypeptide-toxin hybrid protein
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
US4797359A (en) * 1983-05-10 1989-01-10 Board Of Regents, The University Of Texas System Heat shock regulated production of selected and fused proteins in yeast
EP0136798A3 (de) * 1983-08-25 1986-02-19 Biotech Research Laboratories Inc. Titrierungsplatte und Testsatz zum Nachweis von Antikörpern in menschlichem Serum und ihre Herstellung und Verwendung
GB8423659D0 (en) † 1984-09-19 1984-10-24 Pasteur Institut Cloned dna sequences
US5173400A (en) * 1983-09-15 1992-12-22 Institut Pasteur Antibody detection of antibodies to viral proteins in serum
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
FR2571968B1 (fr) * 1984-10-18 1989-03-17 Pasteur Institut Virus purifie des lymphadenopathies et du syndrome d'immuno-depression acquise et antigenes d'enveloppe de ce virus, procede d'obtention de ce virus et de ces antigenes d'enveloppe de ce virus, applications de ce virus ou de ces antigenes a la preparation de compositions immunogenes ou pour le diagnostic des susdites affections.
JPS6061534A (ja) * 1983-09-16 1985-04-09 Kyowa Hakko Kogyo Co Ltd 成人ｔ細胞白血病ウイルス抗原ペプチド
US4519857A (en) 1983-10-05 1985-05-28 Natmar, Inc. Elastic band sealer apparatus and method for forming a continuous non-overlapping band
US5374519A (en) * 1983-12-05 1994-12-20 Institut Pasteur Oligopeptides comprising p18 protein of human immunodeficiency virus (HIV), compositions comprising peptides of p18 protein of HIV, and diagnostic kits and methods for detecting acquired immune deficiency syndrome (AIDS)
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0152030A3 (de) * 1984-02-03 1986-08-13 Juridical Foundation Japanese Foundation for Cancer Research Adult-T-Zell-Leukemiavirus-Antigenpolypeptid
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US4652599A (en) * 1984-04-23 1987-03-24 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS using permissive cells
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
IE58321B1 (en) * 1984-04-23 1993-09-08 Us Health Isolation of proteins of HTLV-III, serological detection of antibodies to HTLV-III in sera of patients with aids and pre-aids conditions, and detection of HTLV-III infection bi/immuno-assays using HTLV-III infection by immuno-assays using HTLV-III and its proteins
JPS60226658A (ja) * 1984-04-25 1985-11-11 Matsushita Electric Works Ltd 加熱器
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
US4716102A (en) * 1984-08-15 1987-12-29 Regents Of The University Of California Purified AIDS-associated virus ARV-2
IL76082A (en) † 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
DE3431140A1 (de) * 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg Enhancer fuer eukaryotische expressionssysteme
JPS6226300A (ja) * 1984-10-10 1987-02-04 セントコ−・インコ−ポレ−テツド Ｈｔｌｖ−３ｄｎａのクロ−ニングおよび発現
DE3588254T2 (de) * 1984-10-18 2008-06-26 Institut Pasteur GAG-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US4725669A (en) * 1984-11-09 1988-02-16 President And Fellows Of Harvard College Assay for detecting infection by human T-cell lymphotropic virus-III
EP0187041B1 (de) 1984-12-24 1996-05-15 Genentech, Inc. Fusionen von AIDS-verwandten Polypeptiden
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
WO1986006414A1 (en) 1985-04-29 1986-11-06 Genetic Systems Corporation Synthetic antigens for the detection of aids-related disease
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
US5175098A (en) * 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to HIV
US5306614A (en) * 1986-01-22 1994-04-26 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2(HIV-2)
US5079342A (en) * 1986-01-22 1992-01-07 Institut Pasteur Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
US5066782A (en) * 1986-01-22 1991-11-19 Institut Pasteur Retrovirus capable of causing AIDS, means and method for detecting it in vitro
US5310651A (en) * 1986-01-22 1994-05-10 Institut Pasteur DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
IE872455L (en) * 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5169753A (en) * 1989-06-05 1992-12-08 Genelabs Incorporated Method and kit for detecting human retrovirus
WO1992006990A1 (en) * 1990-10-17 1992-04-30 The United States Of America, Represented By The Secretary, United States Department Of Commerce Molecular clones of hiv-1 and uses thereof

Also Published As

Publication number Publication date
JPH07311199A (ja) 1995-11-28
EP1245678A3 (de) 2002-10-09
EP0518443A1 (de) 1992-12-16
JPH07313184A (ja) 1995-12-05
DE3587394T3 (de) 2004-02-26
DE10399037I1 (de) 2006-06-08
ATE295881T1 (de) 2005-06-15
HK102495A (en) 1995-06-30
DE3588253D1 (de) 2005-07-14
DE3588252D1 (de) 2005-06-23
DE3588253T2 (de) 2006-02-16
NL300137I1 (nl) 2004-02-02
DE122005000031I1 (de) 2005-10-13
DE1245678T1 (de) 2003-09-18
CA1341423C (en) 2003-03-04
JP2004081219A (ja) 2004-03-18
EP1245678A2 (de) 2002-10-02
US6458527B1 (en) 2002-10-01
US5156949A (en) 1992-10-20
JPH09235297A (ja) 1997-09-09
EP1245678B1 (de) 2005-06-08
EP0181150A1 (de) 1986-05-14
EP0181150B1 (de) 1993-06-09
ATE297468T1 (de) 2005-06-15
US6531276B1 (en) 2003-03-11
US7408053B1 (en) 2008-08-05
US5688688A (en) 1997-11-18
DE3587394D1 (de) 1993-07-15
DE3587394T2 (de) 1994-01-05
LU91049I2 (fr) 2004-01-26
DE3588252T2 (de) 2006-02-02
NL300197I1 (de) 2005-08-01
JP2005137383A (ja) 2005-06-02
JPS61173782A (ja) 1986-08-05
DE10399037I2 (de) 2004-05-06
JP2865283B2 (ja) 1999-03-08
EP0181150B2 (de) 2003-03-12
JPH11341992A (ja) 1999-12-14
EP0518443B1 (de) 2005-05-18
CA1341482C (en) 2005-05-10
NL300137I2 (nl) 2005-11-01

Similar Documents

Publication Publication Date Title
ATE90384T1 (de) Rekombinante virusproteine begleitet von lymphadenopathischem syndrom und/oder ''acquired immune deficiency syndrome'' (aids).
FI873141A0 (fi) Daeggdjurs interleukin-4.
DZ467A1 (fr) Interferon immunitaire urbain.
ATE99330T1 (de) Rekombinantes viren-ueberzugsprotein assoziiert mit ''acquired immune deficiency syndrome'' (aids) und verfahren zur testung von aids.
DE3650175D1 (de) Synthetische antigene zum nachweis von aids.
FI935808A (fi) Hepatit-C-virus (HCV) polypeptider
DE59504181D1 (de) Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
DE3583347D1 (de) Klonieren von dna fuer protozoenantigene.
DE3650019D1 (de) Expression von Virusproteinen mit immunologischer Aktivität.
ES2080047T3 (es) Peptidos hiv y metodos para la deteccion de hiv.
ES2054743T3 (es) Muteina de beta-galactosidasa enzimaticamente inactiva e inmunologicamente activa.
DE3770206D1 (de) Schnellnachweis von n.-gonorrhoe ohne kultur.
DE3852762D1 (de) Expression der immunoaktiven proteine von menschlichem b-lymphotropikvirus.